Brief: Oragenics Engages KBI Biopharma To Support Development Of Intranasal Covid-19 Vaccine Candidate Nt-Cov2-1
10/03/2022 12:32
March 10 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS ENGAGES KBI BIOPHARMA TO SUPPORT DEVELOPMENT OF
INTRANASAL COVID-19 VACCINE CANDIDATE NT-COV2-1
* ORAGENICS INC - KBI TO PRODUCE MATERIAL FOR USE IN FUTURE
EXPECTED PHASE 2 CLINICAL TRIAL OF ORAGENICS' INTRANASAL VACCINE
CANDIDATE
Source text for Eikon: ID:nBwbcfB8Ca
Further company coverage: OGEN.A
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing